Cyclophosphamide Pregnancy and Breastfeeding Warnings
Cyclophosphamide Pregnancy Warnings
Cyclophosphamide has been assigned to pregnancy category D by the FDA. While normal newborns have been delivered to women who were exposed to cyclophosphamide during pregnancy, human data have revealed evidence of embryotoxicity and fetotoxicity. If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant during therapy. The use of cyclophosphamide during pregnancy is contraindicated.
The use of cyclophosphamide during human pregnancy has resulted in severe and multiple abnormalities, including facial and palate defects, absent fingers and toes, absence of some coronary arteries, imperforate ani, hernias, growth retardation, multiple eye defects, microcephaly, hypotonia, and pancytopenia. Normal pregnancies and infantile development have resulted despite the use of cyclophosphamide during pregnancy. Use of this drug during the second and third trimesters does not seem to place the fetus at risk for congenital abnormalities. Nevertheless, use of cyclophosphamide during pregnancy is contraindicated.
Cyclophosphamide Breastfeeding Warnings
Cyclophosphamide has been found in human milk up to 6 hours after a single 500 mg IV dose. Absolute neutropenia has been described in a nursing infant whose mother received 800 mg of cyclophosphamide, along with vincristine and prednisone therapy. Neutropenia and thrombocytopenia were observed in another nursing infant whose mother received 6 mg/kg/day of cyclophosphamide IV. After the third dose, the nursing infants leukocyte an platelet counts fell from pretreatment values of 4,800/mm3 and 270,000/mm3 to 3,200/mm3 and 47,000/mm3, respectively.
Cyclophosphamide is excreted into human milk. Neutropenia, thrombocytopenia, and immune suppression have been observed in infants whose mothers were receiving this drug during lactation. The drug also has an unacceptable risk of carcinogenesis. The American Academy of Pediatrics considers the use of cyclophosphamide to be contraindicated during breast-feeding.
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.